Market Signal Briefing

Bitcoin slips below $66,000, U.S. stock futures bleed as Iran conflict intensifiesIran has reportedly stepped up attacks against U.S. assets in the middle east. Updated Mar 2, 2026, 7:19 a.m. Published Mar 2, 2026, 7:12 a.m.

Bitcoin BTC$66,227.89 pulled back from Asian session highs alongside losses in the U.S. stock futures as Iran stepped up attacks in the Middle East.

The leading cryptocurrency fell back below $66,000 after hitting a high of nearly $67,000 in early Asian hours. The S&P 500 e-mini futures fell to 6,790, down 1.4% on the day, reversing the early rise to 6,857. Meanwhile, oil prices continued to trade higher by over 7% on both sides of the Atlantic.

Iran reportedly stepped up missile attacks on the U.S. assets in Bahrain, Kuwait and the UAE, according to several open source intelligence (OSINT) sources on X. It also attacked Saudi Arabia's oil infrastructure, the widely-followed War & Gore OSINT handle said. Saudi Arabia is one of the largest oil producers in the world.

Meanwhile, according to BBC, Israel launched carried out another round of airstrikes in Lebanon, targeting Iran's premier regional proxy, Hezbollah.

The conflict began Saturday after the U.S. and Israel attacked Israel in what has been described as a pre-emptive move to cripple its missile arsenal and nuclear ambitions.

More For You

Over $9 billion flees bitcoin and ether ETFs in four months

1 hour ago

Record outflows indicate that institutional appetite for digital assets has collapsed.

What to know:

Bitcoin ETFs have seen $6.39 billion in redemptions over four consecutive months, while ether ETFs have lost $2.76 billion in the same period.Bitcoin and ether prices have plunged from their 2025 peaks.

Ark Invest founder Cathie Wood said on Thursday that the firm's conviction in Bitcoin's (CRYPTO: BTC) potential has strengthened despite the ongoing drawdown, but lowered the 2030 target from $1.5 million. Stablecoin Adoption Impacting Wood's Bull Case During an interview with Morningstar Europe, Wood reiterated Bitcoin's position as a global, digital asset with “no government oversight.

TLDR Arthur Hayes, BitMEX co-founder, predicts escalating US-Iran tensions may force the Federal Reserve into rate reductions and expanded money supply Hayes identifies a recurring trend dating back to 1985 connecting major Middle East military operations to subsequent Fed monetary loosening Historical precedents include the Gulf War, post-September 11 conflicts, and the 2009 Afghanistan troop expansion While maintaining a bullish long-term Bitcoin outlook, Hayes recommends investors delay purchases until Fed policy actually shifts At publication time, Bitcoin traded near $66,200, representing approximately 47% decline from peak levels In an essay released March 2, BitMEX co-founder Arthur Hayes presented his thesis that escalating US military engagement with Iran increases the probability of Federal Reserve interest rate reductions and quantitative easing measures.

According to Hayes, such monetary policy shifts would create favorable conditions for Bitcoin price appreciation.

His analysis rests on what he identifies as a consistent pattern spanning nearly four decades. Since 1985, Hayes observes, every American president has initiated Middle Eastern military campaigns, with the Federal Reserve subsequently implementing accommodative monetary policy.

Hayes highlighted three historical case studies. The 1990 Gulf War saw the Fed implement rate cuts in November and December despite persistent inflation driven by elevated oil prices.

Following the September 11, 2001 terrorist attacks, Federal Reserve Chairman Alan Greenspan implemented an emergency 50-basis-point rate reduction. The ensuing Afghanistan and Iraq wars coincided with prolonged monetary easing.

By 2009, when President Obama authorized the Afghanistan troop surge, interest rates had already reached zero and quantitative easing programs were underway.

Hayes contends Trump’s Iran strategy mirrors this established pattern. He suggests bipartisan consensus on Iranian regime change since 1979 provides political justification for Fed accommodation supporting military objectives.

Following weekend airstrikes by US and Israeli forces that resulted in the death of Supreme Leader Ali Khamenei, President Trump committed to continuing operations.

Hayes Urges Caution Before Buying Despite presenting a bullish case, Hayes stops short of recommending immediate purchases. He advises investors to wait for concrete Fed action—actual rate cuts or money printing—before increasing Bitcoin or cryptocurrency allocations.

“The time to back up the truck and buy Bitcoin and high-quality shitcoins is immediately after the Fed cuts rates and or prints money,” he wrote.

He also acknowledged uncertainty about how long Trump will stay committed to the conflict. He called the “prudent action” to wait and see.

Where Bitcoin Stands Now When Hayes released his analysis, Bitcoin was changing hands around $66,200. This represents roughly a 30% year-over-year decline and sits approximately 47% beneath its October 2025 record high of $126,000.

The cryptocurrency has experienced five consecutive months of losses. The Crypto Fear and Greed Index continues registering extreme fear readings.

Broader market reaction to Iran developments remained relatively muted. Monday’s US stock futures showed only modest declines. The S&P 500 dropped less than 1%.

BREAKING: Oil prices officially drop back below $70/barrel, now up just +3.5% on the day.

Oil markets have now erased nearly 70% of their opening move higher.

This is NOT World War 3. Ignore the noise. pic.twitter.com/Q5nIg86uzw

— The Kobeissi Letter (@KobeissiLetter) March 2, 2026

Crude oil prices initially surged but subsequently retraced approximately half their gains. Macro analysis newsletter The Kobeissi Letter observed the futures market opening was “not anywhere near WW3.”

Cryptocurrency social media platforms registered increased “World War 3” discussion over the weekend according to analytics provider Santiment, though mention volume remained below levels seen during June 2025 Israel-Iran tensions.

Bitcoin declined approximately 1.9% during the day at time of publication.

Barclays' Ajay Rajadhyaksha states oil price spikes from geopolitical tensions have historically been brief, advising focus on longer-dated futures over spot prices. He views copper declines, tied to AI capex, as a more critical signal of economic slowdown than oil.

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ: ICLR) concerning potential violations of the federal securities laws.

The magnitude of the single-day decline wiped out billions of dollars of shareholder value and represented one of the largest percentage drops in the CRO sector in recent years. Prior to the disclosure, ICLR had traded in a range that reflected investor confidence in the company's reported financial trajectory and full-year 2025 guidance. The abruptness of the sell-off suggests the market had not priced in any risk of a revenue overstatement or an earnings-release delay. Analyst consensus heading into the fourth quarter had been calibrated to the company's stated full-year revenue range of $8.05 billion to $8.1 billion and adjusted EPS guidance of $13.00 to $13.20--figures that management affirmed as recently as October 23, 2025, without qualification.

The disclosure that prompted the sell-off was concise: the company stated it had identified a preliminary revenue overstatement of under two percent per year for fiscal years 2023 and 2024 and would delay the release of its Q4 and full-year 2025 results. CEO Barry Balfe had previously told investors the company's performance was "broadly in line with expectations" and that he expected "conditions to remain broadly similar throughout the rest of the year." CFO Nigel Clerkin had reported Q3 2025 revenue of $2.043 billion with a year-over-year increase of 0.6 percent, a comparison drawn from the now-questioned prior-year figures.

In the quarters preceding the disclosure, ICON had repurchased $750 million of its own stock and its board had approved a new $1 billion buyback authorization, signaling confidence in the company's financial position. A January 7, 2026 filing stated that full-year 2026 guidance would be issued "alongside the release of our fourth quarter and full-year 2025 results"--a timeline that was rendered moot by the subsequent delay announcement.

If you suffered a loss on your ICON Public Limited Company securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285893

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Stellantis N.V. ("Stellantis N.V.") (NYSE: STLA) concerning potential violations of the federal securities laws.

A review of the timeline highlights a sequence of signals that preceded the February 6 disclosure. On January 31, 2026, Wall Street Zen downgraded STLA to Sell. On February 3, Morgan Stanley followed with a downgrade to Equal-Weight, referencing an "investment lag." On February 5, a report indicated that Stellantis was seeking European cash to offset tariff-related headwinds, hinting at cash-flow stress. Yet the company's most recent earnings call--Q3 2025 on October 30, 2025--was over 90 days old, and no interim update or Form 8-K addressed the deterioration in EV program assumptions that would culminate in the 22 billion charge. In other words, more than three months elapsed between the last earnings discussion and the write-down disclosure, during which the company's forward-looking EV narrative remained intact.

The February 6 announcement marked a stark reversal. Management conceded that the pace of EV adoption had been overestimated, prompting a strategic reset that included suspending the 2026 dividend and placing the dividend policy under review. Shares declined approximately 28% on the NYSE in a single session, representing what multiple outlets described as the worst trading day in the stock's history.

The investigation is focused on whether Stellantis' public communications during the period between the Q3 2025 earnings call and the February 6 disclosure accurately reflected the company's internal understanding of the viability and valuation of its EV assets.

If you suffered a loss on your Stellantis N.V. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285894

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Amid recent market volatility, the opportunity to buy blue chip dividend stocks at more-than-reasonable prices has opened up. Typically, these stocks trade at premium valuations, reflecting their quality and earnings consistency.

However, in some cases, even top dividend stocks have come under pressure amid fears about the disruptive effects of artificial intelligence across numerous sectors. In other situations, top dividend stocks have pulled back due to the market's initial negative reaction to corporate changes that could pay off in the long term.

Alongside this, there are dividend stocks that, while continuing to climb, remain undervalued as prospects improve. The following three stocks are prime examples for each category: Automatic Data Processing (ADP 1.83%), Genuine Parts (GPC +2.05%), and Altria Group (MO 0.67%). Each one is a Dividend King, or a stock that has raised dividends annually for more than 50 consecutive years.

Image source: Getty Images.

Investors have thrown Automatic Data Processing out with the bathwater Automatic Data Processing, better known as ADP, has pulled back not just on AI fears but also on concerns about the sluggish state of the U.S. employment market. Anticipating worse-than-expected results, investors have bailed on ADP, sending it to multi-year lows.

Today's Change

(

-1.83

%) $

-4.00

Current Price

$

214.36

However, in the case of this payroll processing and managed HR services company's shares, the market has thrown the baby out with the bathwater. Following the pullback, ADP's forward yield has climbed to over 3%.

Meanwhile, the company has not only continued to raise dividends by double digits but also raised guidance. This year, management expects revenue and earnings growth of 6% and 11%, respectively. If guidance proves accurate, the stock, trading for 21 times earnings, could move to its historic valuation of around 25 times earnings.

Take advantage of Genuine Parts' post-earnings plunge Following Genuine Parts' release of fourth-quarter 2025 earnings on Feb. 17, shares in the automotive and industrial parts distributor fell by nearly 15%. The stock has continued to decline. Even a more bullish development came alongside weak results and guidance.

Today's Change

(

2.05

%) $

2.40

Current Price

$

119.26

That is, the company plans to split its automotive and industrial businesses into two separate companies early next year. Weak demand within the automotive segment could keep weighing on shares ahead of the split.

However, long-term, the split could unlock tremendous value, based on how Wall Street values industrial parts distributors like Fastenal and W.W. Grainger. In the meantime, investors holding Genuine Parts can collect its 3.6% dividend. The company has 71 consecutive years of dividend growth. The latest increase, announced alongside the earnings report, was 3.2%.

Altria Group has room to run Altria Group, parent company of Philip Morris USA, has been running hot year to date. This comes despite Altria's relative lack of progress in adapting to ongoing changes in tobacco and nicotine consumption habits.

Today's Change

(

-0.67

%) $

-0.47

Current Price

$

69.00

Altria remains largely a cigarette manufacturer, while peers such as Philip Morris International generate an increasing share of their total revenue from non-cigarette tobacco products. Still, 6%-yielding Altria, one of the high-yield dividend stocks, could keep climbing.

As cigarette prices increase, enabling modest earnings growth, concerns about the sustainability of dividend growth keep dissipating. Despite past failures, such as its investment in Juul or the acquisition of NJOY, any further effort to tap into the "smoke-free" market could elicit a bullish response from investors.

The companies have been developing the industry’s first inter-carrier operational model on the ServiceNow AI Platform, helping carriers identify and resolve roaming issues faster and deliver more reliable connectivity for travelers around the world

BARCELONA, Spain--(BUSINESS WIRE)--Mobile World Congress: NTT DOCOMO, StarHub, and ServiceNow, the AI control tower for business reinvention, today introduced a joint initiative to keep travelers connected with autonomous roaming resolution using ServiceNow CRM. The companies have been developing the industry’s first inter-carrier operational model on the ServiceNow AI Platform, helping carriers identify and resolve roaming issues faster and deliver more reliable connectivity for travelers around the world.

When a roaming customer loses service overseas, multiple carriers must coordinate to fix it. Today, without industry-wide standards, each carrier uses its own intake channels — web forms, email, and portals — delaying issue reporting and tracking between operators. For international travelers, that's a dead phone when they need it most. For operators, that's lost revenue, eroded customer trust, and competitive disadvantage in markets where seamless connectivity is expected.

DOCOMO has been working with ServiceNow since 2021 to eliminate manual intervention with Zero-Touch Operation (ZTO), automating remote maintenance tasks that previously required hands-on support. The result is faster fault recovery and elimination of overnight support shifts. Now, DOCOMO, StarHub, and ServiceNow are extending that automation across carrier boundaries to handle inter-carrier operations the same way — automatically, in real time.

The three companies have created a shared operational model that uses AI, data, and workflows to help carriers fix roaming problems faster. The new solution turns manual processes into autonomous workflows that coordinate roaming fault resolution in real time on the ServiceNow AI Platform. When something breaks, the workflow quickly shows operators what happened, which network is affected, where the issue started, and what is already being done. This approach gives carriers better visibility across networks, reduces manual effort, and delivers true proactive customer service. It also helps them spot issues sooner and resolve them faster, improving service quality for travelers around the world.

Technical validation is underway, and the companies are targeting a commercial launch for the second half of the year. The goal is straightforward: more bars on travelers’ cell phones, standardized operations between carriers, better service quality for international travelers, and a scalable model that works globally.

“This collaboration marks an important step toward improving the reliability of international roaming services for customers around the world,” said Akihiro Hikuma, senior vice president, executive general manager of network division at NTT DOCOMO. “By extending automation beyond individual network domains and introducing a standardized, cooperative model for inter‑carrier operations, we can significantly reduce service interruptions and enhance the transparency and speed of issue resolution. DOCOMO is actively building an open and collaborative ecosystem with diverse partners such as StarHub and ServiceNow, advancing intelligent cross‑border operational automation that improves customer experience and contributes to the evolution of global connectivity.”

“Reliable roaming is essential for travelers who depend on connectivity wherever they go,” said Volkan Sevindik, chief technology officer at StarHub. “By working with DOCOMO and ServiceNow to automate and standardize inter-carrier roaming operations, we are addressing a long-standing industry challenge at its root. This collaboration reflects StarHub’s commitment to putting customer experience at the center of how technology is applied at scale, improving service reliability through intelligent automation so customers can stay connected seamlessly across borders.”

“Our partnership with DOCOMO and StarHub represents a bold step toward a future where telecom operations are predictive, proactive, and seamlessly integrated,” said Rohit Batra, general manager and vice president of industry products at ServiceNow. “With ServiceNow CRM and the unique capabilities of the ServiceNow AI Platform, fault tickets flow automatically, recovery happens in real time, and operations that used to take hours now take minutes.”

“This initiative highlights how open, industry standards-based specifications can enable more consistent and interoperable operations across multiple service providers. By leveraging Mplify’s MEF 113 Trouble Ticketing Business Requirements and Use Cases standard, the collaboration shows how operators can reduce fragmentation and manual processes in favor of standardized models that support international roaming at scale,” said Pascal Menezes, chief technology officer at Mplify. “Seeing Mplify specifications applied across multi-operator environments is an important step toward improving service continuity and advancing global interoperability.”

About NTT DOCOMO

NTT DOCOMO is Japan’s largest mobile operator, serving more than 90 million subscribers and leading the industry with its advanced mobile network technologies, including 3G, 4G, and 5G. Under the slogan “Bridging Worlds for Wonder & Happiness,” the company is expanding beyond traditional mobile services and working closely with global partners to deliver exceptional value and drive innovation across the telecommunications and technology sectors.

About StarHub

StarHub is a leading homegrown Singapore company that delivers world-class communications, entertainment, and digital services. With our extensive fiber and wireless infrastructure and global partnerships, we bring to people, homes and enterprises quality mobile and fixed services, a broad suite of premium content, and a diverse range of communication solutions. We develop and deliver solutions incorporating artificial intelligence, cybersecurity, data analytics, Internet of Things, and robotics for corporate and government clients.

StarHub is committed to conducting our business sustainably and responsibly. StarHub is named among TIME’s World’s Most Sustainable Companies 2025 and ranked as the world’s most sustainable wireless telecommunication provider on the Corporate Knights Global 100 (2025). StarHub also ranks 187 on the FORTUNE Southeast Asia 500 in 2025. Listed on the Singapore Exchange mainboard, StarHub is a component stock of the SGX iEdge Singapore Low Carbon Index, iEdge-OCBC Singapore Low Carbon Select 50 Capped Index; as well as the FTSE4Good Index series.

About ServiceNow

ServiceNow (NYSE: NOW) is the AI control tower for business reinvention. The ServiceNow AI Platform integrates with any cloud, any model, and any data source to orchestrate how work flows across the enterprise. By unifying legacy systems, departmental tools, cloud applications, and AI agents, ServiceNow provides a single pane of glass that connects intelligence to execution across every corner of business. With more than 80 billion workflows running on the platform each year, ServiceNow helps organizations turn fragmented operations into coordinated, autonomous workflows that deliver measurable results. Learn how ServiceNow puts AI to work for people at www.servicenow.com.

Press release
Regulated information

Brussels, March 2, 2026, 7.00 am CET

Solvac is closely monitoring the situation and is in close contact with Syensqo’s Board of Directors and management.

Solvac is fully mobilised in its role as a long‑term reference shareholder and is acting alongside Syensqo to support the company through this phase.

Solvac is a public limited company under Belgian law founded in 1983 and listed on the Euronext Brussels stock exchange under the ISIN code BE0003545531 (SOLV). Its assets consist exclusively of a stake of more than 30% in the capital of Solvay SA and in the capital of Syensqo SA. Its titles are exclusively nominative. They may be held freely by individuals or, with the approval of the Board of Directors, by legal entities or similar entities under the conditions set out in their approval policy. As of December 31, 2025, its market capitalization amounted to € 1.75 billion.

For additional information, please contact:

Solvac S.A.
Champs Elysées Street, 43
B-1050 Brussels
Tel. : +32/2/639 66 30
Mail : [email protected]

CP - EN - Syensqo

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Hub Group, Inc. ("Hub Group, Inc.") (NASDAQ: HUBG) concerning potential violations of the federal securities laws.

On February 3, 2026, Hub Group reached a 52-week high of $48.96 per share. Three days later, following the accounting error announcement, shares were trading near $37--a loss of roughly $12 per share in a matter of hours. For an investor holding 10,000 shares, that represents an approximate $120,000 decline in portfolio value.

The analyst community responded with unusual urgency. Stifel, which had maintained a Buy rating and $52 price target, reversed course entirely, downgrading Hub Group to Sell and cutting its target to $27--a 48% reduction. Analyst commentary pointed to the accounting error as a fundamental blow to confidence in the company's reported financials. Baird similarly moved from Outperform to Neutral, reducing its target from $47 to $29, a 38% cut. Both downgrades were issued on the morning of February 6, adding selling pressure to an already declining stock.

Notably, the Q4 2025 earnings headline was not itself negative--Hub Group reported earnings per share of $0.45 versus a consensus estimate of $0.44, and revenue was described as having "topped estimates." However, the positive quarterly result was entirely overshadowed by the restatement disclosure, which affects three prior quarters and an estimated $77 million in understated costs. The disconnect between the modest earnings beat and the 23% stock decline illustrates the market's assessment that the accounting issue is far more consequential than a single quarter's results.

If you suffered a loss on your Hub Group, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285896

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

BARCELONA, Spain, March 02, 2026 (GLOBE NEWSWIRE) -- Space42, the UAE-based AI-powered SpaceTech company, and Viasat, Inc., a global leader in satellite communications, will discuss continued progress toward their planned direct-to-device (D2D) infrastructure and offer an early look at the priorities for Equatys, the companies' forthcoming joint entity, during a co-hosted program at Mobile World Congress in Barcelona this week. The program marks the first public showcase of Equatys' technical direction and commercial vision, reflecting its ambition to accelerate global D2D adoption.   This event brings together policymakers, regulators, and industry leaders to explore how competition, resilience, and sovereignty can be advanced simultaneously, along with enabling new business cases, turning space-enabled mobility into a shared success story for all.

Space42 and Viasat are the cofounders of Equatys, bringing together over 60 years of combined mobile satellite services experience. Equatys is designed as an independent, neutral, multi-participant shared infrastructure platform to extend 3GPP-based connectivity to the billions underserved by terrestrial networks. Since announcing Equatys in September 2025, the cofounders have advanced the program across initiation of venture formation, engineering development, and initial commercial engagement with Mobile Network Operators (MNOs), marking concrete progress toward phased deployment.

Mark Dankberg, CEO and Chairman of Viasat, said: "Space-enabled mobility is a foundational layer for global, seamless connectivity. With Equatys, we are building a platform that empowers nations, operators, and innovators to extend secure, affordable, 3GPP-aligned satellite connectivity to billions. This scalable global model ensures the full ecosystem of participants can benefit from lower barriers to entry, expanded supplier diversity and economies of scale, and stronger competitive dynamics across the value chain.   We are committed to delivering a frictionless end-user experience with seamless handover enabling choice for the carriers. "

Karim Michel Sabbagh, Managing Director of Space42, said: "Equatys reflects disciplined execution against a clear objective: combining the scale of terrestrial networks with the efficiency of space. The collaboration is rooted in Space42's strategy to become a global leader in Non-Terrestrial Networks, and to date has achieved significant engineering milestones, with subscription agreements underway, mobile network operators engaged, and international filings submitted. Equatys demonstrates how space-enabled mobility can modernize legacy Mobile Satellite Services, augment terrestrial networks in lacking areas, and unlock new services across markets."

Ali Al Hashemi, CEO of Space Services at Space42, commented: "Equatys is being built on the principle that shared infrastructure benefits all. The spectrum access model allows nations to retain their sovereign autonomy and licensee control, while advancing satellite capacity with significant cost savings. Combined with a standards-based architecture designed to allow seamless, automatic transition between terrestrial and satellite networks, we intend to scale space-enabled connectivity to those beyond traditional network reach.

Constellation Architecture and Spectrum Strategy

The system is expected to operate initially in globally harmonized L- and S-band MSS spectrum, with technical capability to operate across over 100 MHz of globally allocated and coordinated MSS spectrum. By aligning with 3GPP standards, the platform will integrate terrestrial and satellite networks, enabling seamless transition when terrestrial service becomes unavailable. This will be done while preserving operators’ choice within the -Terrestrial Network ecosystem.

Operating on a Tower Co. model, Equatys intends to deliver the lowest unit cost of satellite capacity while preserving each partner's spectrum rights and sovereign interests. The model is designed to welcome additional cofounders, satellite operators, and spectrum holders as the ecosystem takes shape. Efficient payload and ground technologies are intended to minimize mass-to-orbit requirements while supporting long-term scalability and capital efficiency.

Equatys' shared multi-tenant infrastructure will be supported by up to 2,800 satellites across 60 orbital planes and three altitude layers, deployed by Viasat and Space42. The architecture is intended to densify without fundamental redesign, enabling ecosystem growth at a market-responsive pace and catering to billions of potential users as demand scales.

Commercial Momentum

Space42 has announced partnerships to explore Equatys-enabled D2D connectivity with e& UAE, the flagship telecom arm of global technology group e&, and with PT Telkom Satelit Indonesia (Telkomsat), Indonesia's national satellite operator.

These engagements reflect operator interest in extending coverage through integrated satellite-terrestrial architectures, aligned with national regulatory frameworks and 3GPP standards.

The venture remains subject to definitive agreements, regulatory approvals, and customary closing conditions. The companies intend to provide further updates as Equatys progresses toward formal establishment.

Mobile World Congress

As part of the co-hosted MWC program, Viasat CEO and Chairman Mark Dankberg and Space42 Managing Director Karim Sabbagh will conduct a Fireside Chat to discuss the opportunities and policies shaping the future of space-enabled mobility. The program will explore how the next generation of space-enabled connectivity can be designed to preserve competition, unlock new service capabilities, and align with sovereign priorities, while strengthening resilience and expanding choice.

Attendees can register for the Fireside Chat and other co-hosted panels [here].

About Space42

Space42 (ADX: SPACE42) is a UAE-based AI-powered SpaceTech company that integrates satellite communications, geospatial analytics and artificial intelligence capabilities to enlighten the Earth from space. Formed in 2024 by the successful merger of Bayanat and Yahsat, Space42's global reach allows it to address the rapidly evolving needs of its customers in governments, enterprises, and communities. Space42 comprises two business units: Space Services and Smart Solutions. Space Services focuses on upstream satellite operations for both fixed and mobility satellite services. Smart Solutions integrates geospatial data acquisition and processing with AI to inform decision-making, enhance situational awareness, and improve operational efficiency. Major shareholders include G42, Mubadala, and IHC.

For more information, visit: www.space42.ai; follow us on X: @space42ai

About Viasat

Viasat is a global communications company that believes everyone and everything in the world can be connected. With offices in 24 countries around the world, our mission shapes how consumers, businesses, governments and militaries around the world communicate and connect. Viasat is developing the ultimate global communications network to power high-quality, reliable, secure, affordable, fast connections to positively impact people's lives anywhere they are, on the ground, in the air or at sea, while building a sustainable future in space. In May 2023, Viasat completed its acquisition of Inmarsat, combining the teams, technologies and resources of the two companies to create a new global communications partner. Learn more at www.viasat.com, the Viasat News Room or follow us on LinkedIn, X, Instagram, Facebook, Bluesky, Threads, and YouTube.

Copyright © 2026 Viasat, Inc. All rights reserved. Viasat, the Viasat logo and the Viasat Signal are registered trademarks in the U.S. and in other countries of Viasat, Inc. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

Legal Notice and Cautionary Statement regarding forward-looking information

This announcement may contain forward-looking statements based on current expectations and assumptions about future events. These statements, identified by terms such as "expect," "will," or similar, are subject to risks and uncertainties and may prove inaccurate. They reflect information available as of the date hereof, and the companies disclaim any obligation to update them. No assurance is given that any forward-looking statement will occur, and undue reliance should not be placed on them. This announcement does not constitute a financial promotion or an offer to buy or sell securities in any jurisdiction.

Contact:
Scott Goryl
[email protected] 

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Coty Inc. ("Coty Inc.") (NYSE: COTY) concerning potential violations of the federal securities laws.

Coty's quarterly loss stands out within the global beauty and personal care sector, an industry that has generally posted resilient consumer demand over the past two years. Peers such as Estée Lauder, L'Oréal, and Shiseido reported stable or improving margins in their most recent quarters, making Coty's $126.9 million deficit a notable outlier. The company's like-for-like revenue declined approximately 3% in the quarter, a reversal from the low-single-digit growth the company had guided investors to expect. The magnitude of the EPS shortfall--a 22% miss relative to consensus--placed Coty among the widest negative earnings surprises in the mid-cap consumer space for the reporting period, suggesting the gap between the company's public outlook and its internal trajectory may have been significant.

Alongside the earnings miss, Coty withdrew its full-year FY 2026 guidance and unveiled a new "Coty. Curated." turnaround strategy under interim CEO Markus Strobel, aimed at refocusing the portfolio on core brands. The simultaneous retraction of forward-looking targets and introduction of a restructuring plan compounded the negative reaction among investors and analysts.

Prior to the announcement, Coty's management had expressed optimism about the second quarter during the Q1 FY 2026 earnings call on November 6, 2025. CEO Sue Nabi stated the company expected to be at the "more favorable end of our guidance range" for Q2. The contrast between that characterization and the reported loss has drawn scrutiny.

If you suffered a loss on your Coty Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285897

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws.

On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, approximately $43 million below the $933 million consensus estimate. The EP segment has been positioned as the primary growth engine for the company, driven by its FARAPULSE pulsed field ablation system and related cardiac rhythm management products.

The electrophysiology market represents one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential replacement for traditional thermal ablation procedures. Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has invested heavily in expanding manufacturing capacity and physician training programs. The company projected that global PFA penetration would reach 50% by the end of 2025 and grow to approximately 80% by 2028.

During the Q3 2025 earnings call on October 22, 2025, CEO Mike Mahoney stated the company was "guiding to organic growth of 11% to 13% for fourth quarter '25" and expressed that the company was "incredibly proud of our EP performance, with third quarter sales growing 63%." The company had emphasized EP growth rates of 94% in Q2 2025 and 63% in Q3 2025.

During the first Q&A exchange following the Q4 2025 earnings release, analysts noted the street was expecting approximately 25% EP growth for the quarter. Management's discussion indicated confidence in only approximately 15% growth going forward, representing a significant gap between market expectations and the company's internal outlook.

Following the earnings release, BSX shares fell 17.5% with the stock reaching a 52-week low of $75.50.

If you suffered a loss on your Boston Scientific Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285899

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reduction -

- FENhance 1 is the final study readout of the fenebrutinib pivotal clinical development program in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive multiple sclerosis (PPMS) -

- Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology -

- Totality of data from all three Phase III fenebrutinib studies will be submitted to regulatory authorities -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful and statistically significant results. The study demonstrated that fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, markedly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over a period of at least 96 weeks of treatment, consistent with FENhance 2 results showing a 59% reduction in ARR. Together, these results equate to approximately one relapse every 17 years. Secondary endpoints in both RMS studies show statistically significant and clinically meaningful reductions in brain lesions. Additionally, all progression endpoints show favorable trends for fenebrutinib.

Full data from the FENhance 1 and 2 studies will be shared at the American Academy of Neurology (AAN) Annual Meeting 2026 and submitted to regulatory authorities together with data from the FENtrepid study.

“These pivotal results, together with the earlier data, provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for RMS and PPMS,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “Building on a decade of transforming MS treatment, we are committed to advancing innovation to one day allow people with MS to live a life without disability.”

The positive FENhance 1 study follows positive results for FENhance 2 in RMS and for FENtrepid in PPMS, which were both announced in November. The collective positive results across all three pivotal studies demonstrate that fenebrutinib consistently shows a profound benefit on relapsing and progressive disease biology.

In both RMS studies, liver transaminase elevations were comparable with teriflunomide. In the FENhance 1 study, there was one Hy’s Law case in the fenebrutinib arm and one in the teriflunomide arm. Both cases were asymptomatic and resolved after study drug discontinuation. There were no additional Hy's Law cases across all of the fenebrutinib clinical development program in MS or in other autoimmune diseases.

In the FENhance 1 and 2 studies in RMS, 1 fatal case was reported in the teriflunomide arm and 8 fatal cases with various causes and at different points in treatment in the fenebrutinib arms. Further analyses are ongoing to better understand these findings.

Fenebrutinib targets cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression. Fenebrutinib, a non-covalent BTK inhibitor, is designed to have high potency, selectivity and reversibility. This design allows it to act throughout the body, and also to cross the blood-brain barrier into the central nervous system (CNS) targeting chronic inflammation.

About the FENhance 1 and 2 studies

FENhance 1 and 2 are two Phase III multicenter, randomized, double-blind, double-dummy, parallel-group studies to evaluate the efficacy and safety of investigational fenebrutinib compared with teriflunomide in a total of 1,497 adult patients with RMS. Eligible participants were randomized 1:1 to receive treatment with either oral fenebrutinib twice a day (and placebo matched to oral teriflunomide once a day) or oral teriflunomide once a day (and placebo matched to oral fenebrutinib twice a day) for at least 96 weeks.

The primary endpoint is annualized relapse rate (ARR). Secondary endpoints include total number of T1-gadolinium-enhancing MRI lesions, total number of new and/or enlarging T2-weighted MRI lesions, time to onset of 12-week composite confirmed disability progression (cCDP12) and 24-week cCDP (cCDP24). cCDP incorporates three measures of disability – total functional disability measured by confirmed disability progression (CDP) based on the Expanded Disability Status Scale (EDSS), walking speed measured by the timed 25-foot walk (T25FW) and upper limb function measured by the nine-hole peg test (9HPT).

Following the double-blind treatment period, patients have the option to enter an open-label extension (OLE) phase, in which all patients receive treatment with fenebrutinib.

About fenebrutinib

Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimized pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression.

Fenebrutinib is designed to have high potency and reversibility, with a selectivity for BTK 130 times greater than other kinases. This high selectivity highlights fenebrutinib's potential to bind to its intended target without interfering with other kinases. While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme. These design features may help limit off-target effects.

The fenebrutinib Phase III program includes two similarly designed trials in relapsing multiple sclerosis (RMS) (FENhance 1 and 2) with active comparator teriflunomide and the only trial in primary progressive multiple sclerosis (PPMS) (FENtrepid) in which a BTK inhibitor is being evaluated against Ocrevus.

To date, more than 2,700 patients and healthy volunteers have been treated with fenebrutinib in Phase I, II and III clinical programs across multiple diseases, including multiple sclerosis and other autoimmune disorders.

About multiple sclerosis

Multiple sclerosis is a chronic disease that affects more than 2.9 million people worldwide. People with all forms of multiple sclerosis experience disease progression from the beginning of their disease. Therefore, an important goal of treating multiple sclerosis is to slow, stop and ideally prevent progression as early as possible.

Approximately 85% of people with multiple sclerosis are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Relapsing forms of the disease (RMS) include RRMS and active secondary progressive MS, and people with RMS experience relapses and worsening disability over time. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form of the disease. Until the FDA approval of Ocrevus®, there had been no FDA-approved treatments for PPMS and Ocrevus is still the only approved treatment for PPMS. Despite the availability of CD20s, 30% of patients remain on low-efficacy oral therapy today. Slowing or stopping progression while simultaneously stopping relapses remains a high unmet need in MS.

About Genentech in neuroscience

Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.

About Genentech

Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Indications and Important Safety Information

What is Ocrevus?

Ocrevus is a prescription medicine used to treat:

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults. It is not known if Ocrevus is safe and effective in children.

Who should not receive Ocrevus?

Do not receive Ocrevus if you have an active hepatitis B virus (HBV) infection.

Do not receive Ocrevus if you have had a life-threatening allergic reaction to Ocrevus. Tell your healthcare provider if you have had an allergic reaction to Ocrevus or any of its ingredients in the past.

What is the most important information I should know about Ocrevus?

Ocrevus can cause serious side effects, including:

Infusion reactions: Infusion reactions are a common side effect of Ocrevus, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of Ocrevus for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms: Itchy skin Rash Hives Tiredness Coughing or wheezing Trouble breathing Throat irritation or pain Feeling faint Fever Redness on your face (flushing) Nausea Headache Swelling of the throat Dizziness Shortness of breath Fatigue Fast heartbeat These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion.

If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Infection: Infections are a common side effect. Ocrevus increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with Ocrevus, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of Ocrevus. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with Ocrevus until your infection is gone. Hepatitis B virus (HBV) reactivation: Before starting treatment with Ocrevus, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with Ocrevus. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving Ocrevus. Weakened immune system: Ocrevus taken before or after other medicines that weaken the immune system could increase your risk of getting infections. Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability and has been reported with Ocrevus. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with: Thinking Eyesight Strength Balance Weakness on 1 side of your body Using your arms or legs Decreased immunoglobulins: Ocrevus may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels. Before receiving Ocrevus, tell your healthcare provider about all of your medical conditions, including if you:

have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. have ever had hepatitis B or are a carrier of the hepatitis B virus. have a history of inflammatory bowel disease or colitis. have a history of liver problems have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with Ocrevus. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with Ocrevus and until your healthcare provider tells you that your immune system is no longer weakened. When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with Ocrevus. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with Ocrevus, talk to your healthcare provider. If you have a baby and you received Ocrevus during your pregnancy, it is important to tell your baby’s healthcare provider about receiving Ocrevus so they can decide when your baby should be vaccinated. are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if Ocrevus will harm your unborn baby. You should use birth control (contraception) during treatment with Ocrevus and for 6 months after your last infusion of Ocrevus. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving Ocrevus. are breastfeeding or plan to breastfeed. It is not known if Ocrevus passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Ocrevus. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of Ocrevus?

Ocrevus may cause serious side effects, including:

Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer. Inflammation of the colon, or colitis: Tell your healthcare provider if you have any symptoms of colitis, such as: Diarrhea (loose stools) or more frequent bowel movements than usual Stools that are black, tarry, sticky or have blood or mucus Severe stomach-area (abdomen) pain or tenderness Liver damage. Ocrevus may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start Ocrevus and while you take Ocrevus if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as: yellowing of the skin and eyes (jaundice) nausea vomiting unusual darkening of the urine feeling tired or weak These are not all the possible side effects of Ocrevus.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (888) 835-2555.

For more information, go to https://www.Ocrevus.com or call 1-844-627-3887.

For additional safety information, please see the full Prescribing Information and Medication Guide.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

Corporación América Airports remains undervalued and is enjoying above-average traffic growth. January traffic rose 8.8% year-over-year, driven by 14.8% international growth and a particular 21.8% surge in Argentina's high-margin international traffic. Analyst consensus projects 10% revenue and 41% EPS growth for 2026, with actual revenue likely to exceed estimates due to new concessions and accelerating traffic.

What happenedAccording to a SEC filing dated February 17, 2026, Lightspeed Management Company initiated a new position in Kodiak AI (KDK +1.21%) by purchasing 7,340,475 shares during the fourth quarter. The estimated transaction value was $80.16 million.

What else to knowThis new position represents 5.74% of the fund’s 13F reportable AUM as of December 31, 2025.

Top five holdings after the filing:

NASDAQ:NAVN: $852.66 million (61.1% of AUM)NYSE:NOW: $273.22 million (19.6% of AUM)NASDAQ:KDK: $80.16 million (5.74% of AUM)NYSE:BLND: $70.31 million (5.0% of AUM)NASDAQ:PSNL: $64.96 million (4.7% of AUM)As of Feb. 27, 2026, shares of Kodiak AI were priced at $8.40, up 5.66% since the company went public in September 2025 and outperforming the S&P 500 by 1.51 percentage points in that time.

Company OverviewMetricValuePrice (as of market close February 27, 2026)$8.40Market Capitalization$1.52 billionRevenue (TTM)$16.5 millionNet Income (TTM)-$526 millionCompany SnapshotKodiak AI is a technology company specializing in autonomous driving solutions for commercial and defense applications.

The company leverages a proprietary multi-sensor architecture to deliver scalable AI-powered navigation for complex environments. Its focus on high-reliability autonomy positions it as a differentiated provider in the evolving autonomous vehicle market.

It targets commercial transportation, defense contractors, and industrial fleet operators seeking advanced autonomous vehicle capabilities.

What this transaction means for investorsKodiak AI is a relatively new stock, going public just six months ago. Younger stocks can be riskier in some cases because there’s little historical data to examine, especially regarding how they’ve weathered downturns. Before going public in 2025, the company was launched in 2018.

This makes Lightspeed’s big swing on Kodiak AI even more notable. The stock is now the fund’s third-largest holding, signally a fairly strong conviction in Kodiak’s long-term growth potential.

Kodiak AI is a relatively small player in the self-driving-car space, but it’s already captured the industry’s attention. Last month, Northland named the stock one of its top picks of 2026, with a price target of $17. Cathie Wood’s ARK Invest has also consistently increased its stake in the company.

Kodiak’s long-term success will depend largely on how the autonomous trucking industry fares. If Driving as a Service becomes more widespread, this company could be poised for significant growth.

Katie Brockman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ServiceNow. The Motley Fool has a disclosure policy.

Chinese automakers broadly recorded a sharp drop in sales in February as demand in the world's largest auto industry waned during the Lunar New Year month.

VanEck BDC Income ETF is the largest, most liquid BDC ETF but is highly concentrated in a few names. Recent market dislocation has driven BDC and alternative asset manager equities down 11–12%, raising questions about credit quality and diversification. BIZD's top three holdings account for over 45% of assets, limiting true diversification and making it a concentrated bet rather than a broad BDC play.

Crown Castle (CCI) remains a soft ‘buy' as the $8.5B asset sale should substantially improve leverage and capital allocation flexibility. Despite recent revenue and profit declines, CCI's core tower business remains cash-generative and defensible, with organic growth offsetting some contract headwinds. The DISH Wireless contract termination poses a near-term $220M revenue hit, but interest expense savings and cost cuts are expected to lift adjusted FFO post-sale.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FourWorld Capital Management LLC established a new position in Sable Offshore Corp. (SOC +4.30%) by acquiring 8,105,608 shares. The estimated value of this trade was $73.11 million.

What else to knowThis was a new position for the fund, with Sable Offshore now accounting for 62.9% of reportable AUM as of December 31, 2025.

Top holdings after the filing:

NYSE:SOC: $73.11 million (62.9% of AUM)NYSEMKT:IWM: $6.15 million (5.3% of AUM)NYSE:BMY: $5.39 million (4.6% of AUM)NASDAQ:EVLV: $5.13 million (4.4% of AUM)NYSEMKT:XLE: $4.47 million (3.85% of AUM)As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year and underperforming the S&P 500 by 86.44 percentage points.

Company overviewMetricValuePrice (as of market close Feb. 27, 2026)$8.25Market capitalization$1.20 billionNet income (TTM)-$364 millionCompany snapshotSable Offshore is an energy company focused on offshore oil and gas production, leveraging a portfolio of federal leases totaling approximately 76,000 acres.

The company engages in the production and sale of crude oil and natural gas through offshore California platforms and an onshore processing facility, and it serves energy markets in the United States.

What this transaction means for investorsFourWorld took a major swing on Sable Offshore. The stock is now the firm’s top holding, comprising more than 60% of its portfolio. Considering that all other top holdings make up 5% or less of the fund, FourWorld holds a major conviction in Sable Offshore.

This stock has not been without its challenges. Falling by more than 70% over the last 12 months, the company has faced major legal challenges. Late last year, federal regulators approved the restart of its Las Flores pipeline in California, only for environmental groups to immediately file a lawsuit to halt the restart.

More recently, a Santa Barbara judge ruled against Sable Offshore’s bid to restart the pipeline, further halting its progress. This legal battle could be long and drawn out, increasing the stock’s potential for volatility going forward.

Because the stock has plunged over the last year, it is a more affordable buy. However, much of its success will depend on how it fares with its many legal challenges. While it may have long-term growth potential, it’s also a high-risk buy right now.

Katie Brockman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

MercadoLibre (MELI +1.01%) is an e-commerce powerhouse operating in Latin America and serving 18 countries in the region. It regularly reports strong growth across its business, which includes a large fintech segment, and it has a massive long-term opportunity.

It has a four-digit price tag, trading at $1,768 per share as of this writing. Is it headed to $2,000?

Image source: Getty Images.

Creating a digital revolution in Latin America E-commerce penetration in Latin America is about half that of the U.S., and MercadoLibre is trying to change that, launching new products and improving its value proposition to create the shift. Management said that it sees no reason why the market shouldn't increase, and that its gross merchandise volume (GMV) "could be multiple times larger over the long term."

It starts with the customers. MercadoLibre had 83 million unique active buyers as of the end of 2025, a 24% year-over-year increase. As more customers join the platform, more merchants want to be on it, too, creating a flywheel effect. That brings on more products, and as more business is transacted, the bottom line increases, too.

The fintech segment is complementary to the e-commerce platform, with the Mercado Pago digital wallet one option for paying for purchases. But it has developed into a formidable stand-alone business with nearly 78 million monthly active users as of the end of 2025, a 27% increase, and it offers a large assortment of digital financial services.

In the fourth quarter, management said that it's sacrificing the bottom line right now by investing in new projects that position it for the long term, and that send the price down.

Today's Change

(

1.01

%) $

17.61

Current Price

$

1758.49

Can MercadoLibre stock get back to $2,000? MercadoLibre stock was higher than $2,600 in May last year, and it's down 32% from its high. Investors have had several concerns over the past few months, including a volatile economy in Brazil and the recent margin pressure.

To get back to $2,000, it only needs to gain 14%. Since the stock is fairly cheap at the current price, trading at a forward one-year price-to-earnings ratio of 22 and a price-to-free-cash-flow ratio of 15, it could easily surpass $2,000 if it reports a higher than 14% increase in earnings in its next quarterly results without becoming more expensive. If the market continues to sour on it, it may take longer, but there's a lot to be confident about long-term, and I anticipate it going a lot higher.

BARCELONA, Spain--(BUSINESS WIRE)-- #5G--Aptiv PLC (NYSE: APTV) and Wind River, an Aptiv company and global leader in software for the intelligent edge, is unveiling a proof-of-concept showcasing a mobile-network Vehicle-to-Everything (V2X) solution for sharing of sensor data between vehicles to support advanced safety and automation features leveraging the Verizon Business connected-driving platform Edge Transportation Exchange. Showcasing at MWC Barcelona, the demonstration highlights how vehicles.

LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Alibaba Group Holding Ltd, (“BABA" or the "Company") (NYSE:BABA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. 

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/alibaba-group-holding-ltd. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Palantir’s stock price fell $13.98, or 7.5%, to close at $173.07 per share on October 3, 2025, thereby injuring investors. This occurred following a Reuters report published on October 3, 2025, detailing an Army memo from early September that raised concerns about NGC2, a battlefield communications platform developed by Anduril Industries Inc. and Palantir. The memo alleged the system was flawed, citing “critical deficiencies in fundamental security controls, processes, and governance” and stating that the companies' communications networks were susceptible to “insider threats, external attacks, and data spillage.”

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com 

Attorney Advertising